AB 001 - AKSO Biopharmaceutical
Alternative Names: AB-001 - AKSO BiopharmaceuticalsLatest Information Update: 01 Aug 2022
At a glance
- Originator AKSO Biopharmaceutical
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; IgA nephropathy; Immunological disorders
Most Recent Events
- 27 Jul 2022 Pharmacodynamics data from a preclinical study in Multiple myeloma and Diffuse large B cell lymphoma released by AKSO Biopharmaceutical
- 22 Mar 2022 Preclinical trials in Haematological malignancies in USA (Parenteral) (AKSO Biopharmaceutical pipeline, March 2022)
- 22 Mar 2022 Preclinical trials in IgA nephropathy in USA (Parenteral) (AKSO Biopharmaceutical pipeline, March 2022)